Fig 6.
Kaplan-Meier estimates of overall survival by treatment for patients with anaplastic oligodendroglioma (AO)/anaplastic oligoastrocytoma (AOA) in whom one or neither allele (1p or 19q) was deleted. The hazard ratio (HR) for overall survival of those with noncodeleted AO/AOA treated with procarbazine, lomustine, and vincristine (PCV) plus radiotherapy (RT) compared with those treated with RT alone was 0.85 (95% CI, 0.58 to 1.23; P = .39).